17 terminated. 17 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 17 |
| Phase 1 | 3 | Terminated 3 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery aldesleukin, ipilimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | CINJRegulatory | 9 | 2014-11-26 | 2023-07-18 |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | University of Washington | 23 | 2014-03-01 | 2020-02-13 |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery dabrafenib, trametinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced) | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 13 | 2013-01-01 | 2017-06-23 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib Akt inhibitor MK2206, selumetinib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-01-01 | 2014-06-18 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays - Recurrent Melanoma, Stage IIIc Melanoma | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 12 | 2011-10-01 | 2016-05-30 |
| Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12 - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2011-02-01 | 2016-10-24 |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV temsirolimus, selumetinib, laboratory biomarker analysis - Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2010-10-01 | 2014-05-15 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis - Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 36 | 2010-10-01 | 2016-06-14 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2010-10-01 | 2024-11-19 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox - Recurrent Melanoma, Stage III Melanoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2009-07-01 | 2022-11-15 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma cyclophosphamide, fludarabine phosphate, therapeutic autologous lymphocytes - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 58 | 2005-11-01 | 2013-06-06 |
| Tanespimycin in Treating Patients With Stage III-IV Melanoma tanespimycin, laboratory biomarker analysis - Recurrent Melanoma, Stage III Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 50 | 2004-06-01 | 2013-04-10 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma recombinant fowlpox-TRICOM vaccine, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 28 | 2004-06-01 | 2014-06-09 |
| A Phase II Study of UCN-01 in Metastatic Melanoma 7-hydroxystaurosporine, laboratory biomarker analysis, pharmacological study - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 17 | 2003-11-01 | 2015-03-02 |
| SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated semaxanib, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 35 | 2000-07-01 | 2013-01-24 |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma allogeneic lymphocytes, anti-thymocyte globulin, cyclophosphamide - Stage IV Melanoma, Recurrent Melanoma | Phase 1 / Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1999-01-01 | 2024-03-04 |
Melanoma (17) · Brain Neoplasms (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Skin Neoplasms (1) · Small Cell Lung Carcinoma (1) · Uveal Melanoma (1)
Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Germ Cell and Embryonal (17) · Neoplasms, Nerve Tissue (17) · Neuroectodermal Tumors (17) · Neuroendocrine Tumors (17) · Nevi and Melanomas (17) · Skin Diseases (17) · Skin and Connective Tissue Diseases (17) · Neoplasms (16) · Skin Neoplasms (16) · Brain Diseases (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Interleukin-2 (3) · aldesleukin (3) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · AZD 6244 (2) · Biopsy (2) · CTLA-4 Antigen (2) · Cyclophosphamide (2) · Immunohistochemistry (2) · Ipilimumab (2) · MART-1 Antigen (2) · Radiosurgery (2) · 7-hydroxystaurosporine (1) · Antilymphocyte Serum (1) · Axitinib (1) · Filgrastim (1)
National Cancer Institute (NCI) (10) · Vanderbilt-Ingram Cancer Center (2) · CINJRegulatory (1) · Fred Hutchinson Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Roswell Park Cancer Institute (1) · University of Washington (1)
United States (17)
Thomas Gajewski (3) · Howard Kaufman (1) · Jeffrey Sosman (1) · Jeffrey Sosman, MD (1) · Kim Margolin (1) · Mark Kelley (1) · Matuesz Opyrchal, MD (1) · Morris D Groves (1) · Paul Chapman (1) · Ragini Kudchadkar (1) · Ramesh Rengan (1) · Richard W. Childs (1) · Scott Christensen, MD (1) · Steven Rosenberg (1) · Sylvia Lee (1)
PMID 20967484, PMID 25250858, PMID 25797743, PMID 31998643
P30CA014599 (2), K12CA076930 (1), N01CM00039 (1), N01CM00071 (1), N01CM00100 (1), N01CM17101 (1), N01CM17102 (1), N01CM62206 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P30CA072720 (1), P30CA076292 (1), R21CA137647 (1), U01CA062461 (1)